OmniBind: Proteome-Wide Promiscuity Predictions for Early-Stage Drug Screening

Read full text Summarise with VIRAT
Authors: Josef Hanke, Sebastian Pujalte Ojeda, Ruoh Wen Cheong, Logan M. Glasstetter, Ellis Baker, Hilbert Yuen In Lam, Michaela Brezinova, Adelie Auriane Berenice Louet, Shengyu Zhang, Michele Vendruscolo
Cited by: 0
References: 55

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Off-target binding remains a leading cause of drug attrition, yet no method exists for rapidly quantifying small-molecule promiscuity across the human proteome. Here, we define promiscuity as the mean predicted binding affinity over 15,405 human proteins and derive a specificity score combining target affinity with this proteome-wide distribution. To make this assessment tractable at scale, we introduce OmniBind, a message-passing neural network that predicts promiscuity directly from a SMILES string at about a thousand compounds per second, several orders of magnitude faster than proteome-wide profiling. OmniBind promiscuity scores correlate with experimental binding data near assay reproducibility limits. Ranking candidates by specificity rather than affinity alone improves enrichment of approved drugs across all thresholds tested, an advantage robust to the choice of affinity predictor. OmniBind fills an unoccupied niche in the early-stage screening landscape as a fast, proteome-scale complement to traditional safety panels, with accuracy that will scale as the underlying affinity predictors continue to improve.

Fields of Study & Subjects

Computational Drug Discovery Methods Protein Degradation and Inhibitors vaccines and immunoinformatics approaches

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
18 March 2026
Language
EN
Document type
Preprint